# Mesa Laboratories Inc: Form 10-Q for the period ended Jun 30, 2020

- Company: [Mesa Laboratories Inc](/companies/mlab.md) (CIK 724004)
- Form: 10-Q
- Filed: 2020-08-06
- Accepted by EDGAR: Aug 6, 2020, 08:05 ET
- Period: 2020-06-30
- Accession: 0001437749-20-016748
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/724004/000143774920016748/mlab20200630_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/724004/000143774920016748/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-04-01 to 2020-06-30 | $29.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2020-04-01 to 2020-06-30 | $10.0m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2020-04-01 to 2020-06-30 | $20.0m | us-gaap:GrossProfit |
| Research and development | 3 months, 2020-04-01 to 2020-06-30 | $2.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2020-04-01 to 2020-06-30 | $3.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2020-04-01 to 2020-06-30 | $1.9m | us-gaap:InterestExpense |
| Income tax | 3 months, 2020-04-01 to 2020-06-30 | −$643.0k | us-gaap:IncomeTaxExpenseBenefit |
| Diluted EPS | 3 months, 2020-04-01 to 2020-06-30 | $0.22 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2020-04-01 to 2020-06-30 | $0.23 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2020-04-01 to 2020-06-30 | 4,669,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2020-04-01 to 2020-06-30 | $2.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2020-04-01 to 2020-06-30 | $216.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months, 2020-04-01 to 2020-06-30 | $704.0k | us-gaap:PaymentsOfDividends |
| Cash and equivalents | at 2020-06-30 | $231.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-06-30 | $269.8m | us-gaap:AssetsCurrent |
| Total assets | at 2020-06-30 | $576.7m | us-gaap:Assets |
| Current liabilities | at 2020-06-30 | $20.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-06-30 | $194.5m | us-gaap:Liabilities |
| Shareholders' equity | at 2020-06-30 | $382.2m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 37,211 characters.

#### (Dollars in thousands, except per share amounts)

### Forward Looking Statements

*This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The forward-looking statements in this Quarterly Report on Form 10-Q do not constitute guarantees of future performance. Investors are cautioned that statements in this Quarterly Report on Form 10-Q which are not strictly historical statements, including, without limitation, express or implied statements or guidance regarding current or future financial performance and position, potential impairment of future earnings, anticipated effects of, and future actions to be taken in response to, the COVID-19 pandemic, management’s strategy, plans and objectives for future operations or acquisitions, product development and sales, product candidate research, development and regulatory approval, selling, general and administrative expenditures, intellectual property, development and manufacturing plans, availability of materials and product and adequacy of capital resources and financing plans constitute forward-looking statements. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which the Company operates, and management’s beliefs and assumptions. The Company undertakes no obligation to publicly update or revise the statements in light of future developments. In addition, other written and oral statements that constitute forward-looking statements may be made by the Company or on the Company’s behalf. Words such as “expect,” “seek,” “anticipate,” “intend,” “plan,” “believe,” “could,” “estimate,” “may,” “target,” “project,” or variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks associated with: the duration and impact of the COVID-19 pandemic and the myriad of its effects on our business including related decreases in customer demand and spending; our ability to successfully grow our business, including as a result of acquisitions; the market acceptance of our products; reduced demand for our products that adversely impacts our future revenues, cash flows, results of operations and financial condition; inability to consummate acquisitions at our historical rate and at appropriate prices, and to effectively integrate acquired businesses; conditions in the global economy and the particular markets we serve; significant developments or uncertainties stemming from the U.S. government, including changes in U.S. trade policies and medical device regulations; the timely development and commercialization, and customer acceptance, of enhanced and new products and services based on technological innovation; laws regulating fraud and abuse in the health care industry and the privacy and security of health and personal information; outstanding claims, legal proceedings, tax audits and assessments and other contingent liabilities; and foreign currency exchange rates and fluctuations in those rates. Further information on potential risk factors that could affect our financial results are included in the filings made by us from time to time with the Securities and Exchange Commission including under the section entitled “Risk Factors” in our Annual Report on Form 10-K, for the year ended March 31, 2020 and our subsequent Quarterly Reports on Form 10-Qs. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.*

### Business Overview

We are a multinational manufacturer, developer, and seller of quality control products and services, many of which are sold into niche markets that are driven by regulatory requirements. We have manufacturing operations in North America and Europe and our products are marketed by our sales personnel in the U.S., Canada, Europe, Japan, and by distributors in these areas as well as throughout the rest of the world. We prefer markets in which we can establish a strong presence and achieve high gross margins. As of June 30, 2020, we managed our operations in four reportable segments, or divisions: Sterilization and Disinfection Control, Instruments, Biopharmaceutical Development, and Continuous Monitoring, each of which are described further in *Results of Operations* below. Non-reportable operating segments (including our Cold Chain Packaging division which ceased operations during the year ended March 31, 2020) and unallocated corporate expenses are reported within Corporate and Other.

As discussed in Note 8. "Stockholders' Equity" within Item 1. "Financial Statements," we completed an equity offering of our common stock, which provided $145,935, net of discounts and issuance costs. We intend to use the money raised for general corporate purposes, which may include furthering our acquisition strategy.

### Corporate Strategy

We strive to create shareholder value and further our purpose of Protecting the Vulnerable® by growing our business both organically and through further acquisitions, by improving our operating efficiency, and by continuing to hire, develop and retain top talent. As a business, we commit to our purpose of Protecting the Vulnerable® every day by taking a customer-focused approach to developing, building, and delivering our products. We serve a broad set of industries that require dependable quality control and calibration solutions to ensure the safety and efficacy of the products they use, and by delivering the highest quality products possible, we are committed to protecting environment, products, and people.

Our revenues come from product sales, which includes hardware and software, and consumables; as well as services, which include installation, discrete maintenance services, and ongoing maintenance contracts. Revenues increase as a result of organic or inorganic revenues growth. Inorganic revenues growth is driven by acquisitions.

We continue to focus on improving our operating efficiency *The Mesa Way*, which is our customer-centric, lean based system for continuously improving and operating a set of high-margin, niche businesses. *The Mesa Way* is based on four pillars:

- **M**easure what matters: We use “True North,” our customer’s perspective, to measure what matters most to customers and to set high standards for performance. We manage to leading indicators, whenever possible, which drives us to proactively avoid problems before they are apparent to our customers.
- **E**mpower Teams: We move decision making as close to the customer as possible and provide the structure and real-time communication forum to align the whole organization towards surpassing customer expectations.
- **S**teadily Improve: We leverage a common and proven set of lean-based tools to identify the root cause of opportunities, prioritize our biggest opportunities, and enable change to be embraced and implemented quickly.
- **A**lways Learn: We ensure that improvements are sustained, enabling us to raise performance expectations and repeat the cycle of improvement. Equally, this cycle strengthens the Mesa team by providing endless learning opportunities for our employees and helps us to become an employer of choice in our communities.

Finally, we hire, develop, and retain top talent, capable of taking on new challenges using a team approach to continuously improve our products, our services, and ourselves, resulting in long-term value creation for our shareholders.

Page 19

### COVID-19 and Business Update

During March 2020, the impact from the spreading of COVID-19 was declared a global pandemic by the World Health Organization and a national public health emergency in the United States. The consequences of the outbreak and impact to the economy have continued to evolve throughout the three months ended June 30, 2020 and we are unable to ascertain the full extent of the impact on our business as of the date of this filing. As was the case as of the end of the year ended March 31, 2020, the pandemic continues to present a substantial public health and economic challenge around the world and is affecting our employees, business operations, and operating segments in various ways.

As COVID-19 has continued to spread and significantly affect markets around the world, we continued to enforce company policies that are focused on ensuring the safety of our employees, while continuing to deliver our goods to customers across the world. Due to the critical nature of our products and services, we are generally exempt from governmental orders in the U.S. and other countries requiring businesses to suspend operations. Nevertheless, the pandemic brought a material disruption to our operations. To protect employees and comply with regulations and recommendations to limit gatherings and increase social distancing, we require office-based employees to work remotely, and we implemented enhanced safety protocols at our manufacturing facilities, including operating with split shifts to reduce the size of the workforce on premises, performing temperature checks at the start of shifts, and maximizing the amount of space between workspaces. We have taken aggressive steps to limit the exposure and enhance the safety of our facilities for employees working so that we can continue to supply products and services to hospitals and other customers. Additionally, we continue working closely with our suppliers to develop contingency plans for potential supply interruptions.

Most of our operating segments have encountered challenges resulting from COVID-19, as the global downturn resulted in a slow-down in demand for many of the products and services that we offer. The impact on our businesses is outlined below:

- Sterilization and Disinfection Control: This division benefited in the three months ended June 30, 2020 from fulfilling temporary advanced buying orders placed by certain customers during the three months ended March 31, 2020; however, overall orders slowed significantly in the three months ended June 30, 2020 as advanced ordering began to reverse. The critical and disposable nature of Sterilization and Disinfection Control products makes them less sensitive to general economic conditions, and the demand for Sterilization and Disinfection Control products has remained fairly strong. Prior to the COVID-19 pandemic, the worldwide market for sterilization and disinfection control products had been growing as more countries focus on verifying the effectiveness of sterilization and disinfection processes and some of the products used in this division can be used support the changing environment resulting from COVID-19.
- Instruments, Biopharmaceutical Development, and Continuous Monitoring: Demand for hardware and certain services sold by our Instruments, Biopharmaceutical Development, and Continuous Monitoring divisions declined during the three months ended June 30, 2020, which we believe was mainly a result of COVID-19. Although demand for the Biopharmaceutical Development division's products has increased in recent years, the global pandemic has inhibited our ability to use proven strategies to market and sell these products. When travel restrictions are lifted and we are able to go on-site at customer facilities, we expect to continue to grow revenues organically in the Biopharmaceutical Development division; however, we expect that demand for hardware sold by our Instruments division will return more slowly.

Sales of our hardware products have historically been more sensitive to general economic conditions than sales of our consumables. The COVID-19 induced economic downturn appears to be behaving similarly, as businesses are postponing spending in response to economic uncertainty, declines in income and asset values, tighter credit, unemployment, and negative financial news. Worldwide and regional economic conditions have reduced the demand for our products and services as our customers reduced or delayed capital equipment and other types of purchases. We expect this trend to continue and to result in lower sales in our Instruments, Biopharmaceutical Development, and Continuous Monitoring divisions until the broader healthcare industry returns to normal levels.

Overall, we anticipate a gradual return to more normal demand for our products as the broader healthcare industry and other served industry verticals slowly return to more normal levels; however, due to outbreaks and increasing levels of COVID-19 in many areas, especially the U.S., strict regulations may be reinstated, inhibiting a return to more normal operations across healthcare and the broader economy. We believe that COVID-19 related uncertainties, restrictions, and suppressed demand will continue to negatively impact our business during the remainder of the year ending March 31, 2021.

Gross profit is affected by our product mix, manufacturing efficiencies, and price competition. Historically, as we have integrated our acquisitions and taken advantage of manufacturing efficiencies, our gross profit percentages for some products have improved. There are, however, differences in gross profit percentages between product lines, and ultimately the mix of sales will continue to impact our overall gross profit.

Page 20

### Results of Operations

Our results of operations and period-over-period changes are discussed in the following section. The tables and discussion below should be read in conjunction with the accompanying Unaudited Condensed Consolidated Financial Statements and the notes thereto appearing in Item 1. *Financial Statements* (in thousands, except percent data).

Overall revenues increased 14%, organic revenues growth declined 4% and gross profit increased 6 percentage points for the three months ended June 30, 2020 compared to the three months ended June 30, 2019. Results by reportable segment are as follows:

|  | Revenues Three Months Ended June 30, 2020 | Three Months Ended June 30, 2019 | Organic Revenues Growth Three Months Ended June 30, 2020 | Three Months Ended June 30, 2019 | Gross Profit as a % of Revenues Three Months Ended June 30, 2020 | Three Months Ended June 30, 2019 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Sterilization and Disinfection Control | $13,067 | $12,110 | 8% | 7% | 76% | 70% |
| Instruments | 7,680 | 9,544 | (20%) | 4% | 61% | 64% |
| Biopharmaceutical Development | 5,949 | - | N/A | N/A | 75% | N/A |
| Continuous Monitoring | 3,245 | 3,317 | (2%) | (13%) | 27% | 38% |
| **Mesa Labs' reportable segments** | $29,941 | $24,971 | **(4%)** | **3%** | **67%** | **63%** |
| Corporate and Other | - | 1,317 | (100%) | (28%) | N/A | 25% |
| Total Company | $29,941 | $26,288 | (4%) | 1% | 67% | 61% |

Our unaudited condensed consolidated results of operations are as follows:

|  | Three Months Ended June 30, 2020 | 2019 | Percentage Change 2020 vs. 2019 |
| --- | ---: | ---: | ---: |
| Revenues | $29,941 | $26,288 | 14% |
| Cost of revenues | 9,973 | 10,149 | (2%) |
| Gross profit | 19,968 | 16,139 | 24% |
| Operating Expenses | 16,770 | 10,747 | 56% |
| Operating Income | 3,198 | 5,392 | (41%) |
| Net income | $1,025 | $4,597 | (78%) |

Page 21

### Reportable Segments

### Sterilization and Disinfection Control

Our Sterilization and Disinfection Control division manufactures and sells biological, cleaning, and chemical indicators. Biological, cleaning, and chemical indicators are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. The division also provides testing and laboratory services, mainly to the dental industry. Sterilization and disinfection control products are disposable and are used on a routine basis, thus product sales are less sensitive to general economic conditions.

|  | Three Months Ended June 30, 2020 | 2019 | Percentage Change 2020 vs. 2019 |
| --- | ---: | ---: | ---: |
| Revenues | $13,067 | $12,110 | 8% |
| Gross profit | 9,977 | 8,505 | 17% |
| Gross profit as a % of revenues | 76% | 70% | 6% |

Sterilization and Disinfection Control revenues increased 8% for the three months ended June 30, 2020, as a result of organic revenues growth, which was achieved primarily through volume increases with existing customers and to a lesser extent, modest price increases. Sales in our Sterilization and Disinfection Control division have been increasing since late in the three months ended March 31, 2020, because several customers ordered larger quantities than usual in an effort to mitigate supply chain risks, which resulted in an increase in our backlog at the end of the fiscal year. During the three months ended June 30, 2020, overall orders slowed significantly as advanced ordering began to reverse and we reduced our backlog significantly.

Sterilization and Disinfection Control gross profit margin percentage increased 6 percentage points for the three months ended June 30, 2020, primarily as a result of efficiencies gained from higher sales volumes and operational improvements.

### Instruments

Our Instruments division designs, manufactures, and markets quality control instruments and consumable products utilized in the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, and environmental air sampling industries. Instrument products have a longer life, and their purchase by our customers is discretionary, so sales are more sensitive to general economic conditions. Service demand is driven by our customers’ quality control and regulatory environments, which require periodic repair and recalibration or certification of our instrument products.

|  | Three Months Ended June 30, 2020 | 2019 | Percentage Change 2020 vs. 2019 |
| --- | ---: | ---: | ---: |
| Revenues | $7,680 | $9,544 | (20%) |
| Gross profit | 4,671 | 6,063 | (23%) |
| Gross profit as a % of revenues | 61% | 64% | (3%) |

Instruments revenues decreased 20% for the three months ended June 30, 2020, as customers across all served markets continued to limit spending that is more discretionary in nature in response to economic uncertainty.

Instruments gross profit margin percentage decreased 3 percentage points during the three months ended June 30, 2020, primarily due to lower sales volumes that reduced our efficiencies.

### Biopharmaceutical Development

Our Biopharmaceutical Development division was created as a result of the GPT acquisition on October 31, 2019. The division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Immunoassays and peptide synthesis solutions accelerate the discovery, development, and manufacturing of biotherapeutic drugs.

|  | Three Months Ended June 30, 2020 | 2019 | Percentage Change 2020 vs. 2019 |
| --- | ---: | ---: | --- |
| Revenues | $5,949 | $- | N/A |
| Gross profit | 4,466 | - | N/A |
| Gross profit as a % of revenues | 75% | -% | N/A |

Biopharmaceutical Development's sales during the three months ended June 30, 2020 were negatively impacted by the economic uncertainty and social restrictions related to the COVID-19 pandemic. Global efforts to stop the spread of COVID-19 and the resulting shut down or slowing of many facets of our society and commerce have resulted in reduced demand as we are unable to market our products at industry conferences or go on-site to most customers' locations to demonstrate the products; however, we are pursuing digital sales efforts to continue to create leads and demonstrate our products to customers.

Biopharmaceutical Development's gross profit includes a $436 reduction in amortization expense as a result of an adjustment booked to the value of an inventory step-up recorded in purchase accounting related to the GPT Acquisition. Gross profit also includes $178 of incremental amortization expense related to the adjustment of the value of technology intangibles that are amortized to cost of revenues. Excluding the amortization catch ups, gross profit for the three months ended June 30, 2020 would have been $4,208, and gross profit margin percentage would have been 71%.

Page 22

### Continuous Monitoring

Our Continuous Monitoring division designs, develops, and markets systems which are used to monitor various environmental parameters such as temperature, humidity, and differential pressure to ensure that critical storage and processing conditions are maintained in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies, and laboratory environments. Continuous monitoring products and systems have a longer life, and their purchase by our customers is discretionary, so sales are sensitive to general economic conditions. Continuous monitoring products may be sold in conjunction with a perpetual or subscription-based software license, which may be required for the related hardware to function. Service demand is driven by our customers’ quality control and regulatory environments, which require periodic repair and recalibration or certification of our continuous monitoring systems.

|  | Three Months Ended June 30, 2020 | 2019 | Percentage Change 2020 vs. 2019 |
| --- | ---: | ---: | ---: |
| Revenues | $3,245 | $3,317 | (2%) |
| Gross profit | 874 | 1,244 | (30%) |
| Gross profit as a % of revenues | 27% | 38% | (11%) |

Continuous Monitoring's revenues decreased 2% for the three months ended June 30, 2020. Beginning late in our year ended March 31, 2020, the business was significantly affected by the shut down and slowing of many facets of the U.S. society and economy in response to the COVID-19 outbreak. Specifically, for most of the three months ended June 30, 2020, our ability to go on-site to many of our customers' facilities to install and service systems was severely restricted. These restrictions were beginning to ease in May, 2020.

Continuous Monitoring gross profit margin percentage decreased 11 percentage points for the three months ended June 30, 2020, primarily due to low service revenues volumes while we continued to pay many of our salaried technicians who were unable to complete revenue-generating orders. We also reorganized the business unit during the three months ended June 30, 2020, which we believe will allow it to operate more efficiently moving forward. This reorganization was one step in our road map to improve the division’s operations and resulting gross profit percentage.

### Corporate and Other

Corporate and Other primarily consists of results from our Cold Chain Packaging division which was dissolved during the year ended March 31, 2020 and is no longer considered a reportable segment, as well as unallocated corporate expenses.

|  | Three Months Ended June 30, 2020 | 2019 | Percentage Change 2020 vs. 2019 |
| --- | ---: | ---: | ---: |
| Revenues | $- | $1,317 | (100%) |
| Gross profit | (20) | 327 | (106%) |
| Gross profit as a % of revenues | N/A | 25% | N/A |

Page 23

### Operating Expenses

Operating expenses for the three months ended June 30, 2020 increased 56% as compared to the prior year.

### Selling

Selling expense is driven primarily by labor costs, including salaries and commissions; accordingly, it may vary with sales levels.

|  | Three Months Ended June 30, 2020 | 2019 | Percentage Change 2020 vs. 2019 |
| --- | ---: | ---: | ---: |
| Selling expense | 4,075 | 2,208 | 85% |
| As a percentage of revenues | 14% | 8% | 6% |

Selling expense for the three months ended June 30, 2020 increased 85% primarily as a result of selling costs incurred by the Biopharmaceutical Development division, partially offset by lower industry conferences and travel costs as we implemented strict travel restrictions for our employees beginning in March, 2020. As a percentage of revenues, selling expense was 14% for the three months ended June 30, 2020, as compared to 8% for the three months ended June 30, 2019. We plan to continue making modest, strategic investments in sales and marketing resources in order to further increase organic revenues growth. In addition, costs associated with the Biopharmaceutical Development division's sales force are expected to continue to result in higher selling expense as a percentage of revenues than we incurred historically; however, increases are expected to begin to normalize once the Biopharmaceutical Development division returns to normal sales levels. In the near-term, we expect total selling expense to approximate 10%-15% of revenues.

### General and Administrative

Labor costs, including non-cash stock-based compensation and amortization of intangible assets drive the substantial majority of general and administrative expense.

|  | Three Months Ended June 30, 2020 | 2019 | Percentage Change 2020 vs. 2019 |
| --- | ---: | ---: | ---: |
| General and administrative expense | 10,099 | 7,520 | 34% |
| As a percentage of revenues | 34% | 29% | 5% |

General and administrative expenses for the three months ended June 30, 2020 increased 34%. The increase was primarily attributable to increased amortization expense associated with intangible assets acquired from the GPT acquisition; higher non-cash stock-based compensation expense, which was almost fully offset by lower bonus expense as certain executives of the Company converted portions of cash bonus incentives to non-cash stock-based compensation expense for the year ending March 31, 2021; and costs associated with the Biopharmaceutical Development division including professional services fees related to the implementation of our enterprise resource planning tool for Biopharmaceutical Development.

Page 24

### Research and Development

Research and development expense is predominantly comprised of labor costs and costs of third-party consultants.

|  | Three Months Ended June 30, 2020 | 2019 | Percentage Change 2020 vs. 2019 |
| --- | ---: | ---: | ---: |
| Research and development expense | 2,596 | 1,019 | 155% |
| As a percentage of revenues | 9% | 4% | 5% |

Research and development expenses for the three months ended June 30, 2020 increased 155% primarily as a result of expenses attributable to the Biopharmaceutical Development division. Including the Biopharmaceutical Development division, we expect research and development expenses will be approximately 7%-10% of revenues in the near term in part depending on the pace of the economic recovery.

### Nonoperating Expense (Income)

|  | Three Months Ended June 30, 2020 | 2019 | Percentage Change 2020 vs. 2019 |
| --- | ---: | ---: | ---: |
| Nonoperating expense | 2,816 | 32 | 8,700% |

Nonoperating expense for the three months ended June 30, 2020 is composed primarily of interest expense associated with our 1.375% convertible senior notes issued in August 2019 (the "Notes"), gains and losses on foreign currency transactions, and gains and losses on sales of property, plant and equipment. Interest expense for the three months ended June 30, 2020 increased by $1,524 compared to the three months ended June 30, 2019 due to interest expense related to the Notes, partially offset by lower interest expense as a result of paying off our credit facility.

### Income Taxes

|  | Three Months Ended June 30, 2020 | 2019 | Percentage Change 2020 vs. 2019 |
| --- | ---: | ---: | ---: |
| Income tax expense | (643) | 763 | (184%) |
| Effective tax rate | (168%) | 14% | (182%) |

Our effective tax rate benefited notably from the exercise of stock options and to a lesser extent, lower pre-tax income. Our income tax rate varies based upon many factors, but in general, we anticipate that on a go-forward basis our effective tax rate as adjusted for the GPT Acquisition will be approximately 25%, plus or minus the impact of excess tax benefits and deficiencies associated with share-based payment awards to employees; see Note 10. “Income Taxes” within Item 1. *Financial Statements* for additional discussion. The excess tax benefits and deficiencies associated with share-based payment awards to our employees have caused and, in the future, may cause large fluctuations in our realized effective tax rate based on timing, volume, and nature of stock options exercised under our share-based payment program.

### Net Income

Net income for the three months ended June 30, 2020 varied with the changes in revenues, gross profit, and operating expenses (which includes $1,268, $3,354, and $1,326 of non-cash: stock-based compensation, amortization of intangible assets acquired in a business combination, and interest expense and discount amortization on the Notes, respectively, partially offset by a $436 benefit associated with a cumulative effect true up of inventory step up amortization).

### Seasonality

Our Biopharmaceutical Development division is subject to modest seasonal fluctuations that align with the budget cycles of our customers. Sales of capital equipment and consumables for that segment are typically the lowest in the first calendar quarter of the year, and highest during the fourth calendar quarter of the year (which is the third quarter of our fiscal year). The other reportable segments are typically not subject to seasonality.

Page 25

### Liquidity and Capital Resources

Our sources of liquidity include cash generated from operations, cash and cash equivalents on hand, working capital and potential additional equity and debt offerings. Our more significant uses of resources have historically included acquisitions, long-term capital expenditures, payment of debt and interest obligations, and quarterly dividends to shareholders. Although the COVID-19 pandemic has resulted in lower sales overall, we continue to believe that we have the liquidity required to continue operations during this volatile period. During the three months ended June 30, 2020, we continued taking steps to reduce cash outlays and expenses, including limiting travel, reducing hiring new employees, and converting a portion of our executives' remuneration from cash to non-cash stock-based compensation incentives.

Even given current macroeconomic conditions, we believe that cash and cash equivalents on hand and cash generated from operations will be sufficient to meet our short-term and long-term needs. Additionally, we believe that we have access to equity and credit markets if necessary. However, additional equity or debt financing, or other transactions, may not be available on acceptable terms, if at all.

Working capital is the amount by which current assets exceed current liabilities. We had working capital of $249,281 and $96,784 at June 30, 2020, and March 31, 2020, respectively. As of June 30, 2020, and March 31, 2020, we had $230,951 and $81,380, respectively, of cash and cash equivalents, which were held primarily in money market funds. We consider all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.

On June 9, 2020, we completed the sale and issuance of 600,000 shares of our common stock and on June 16, 2020, our underwriters exercised in full their option to purchase an additional 90,000 shares of our common stock. The offering price to the public was $225.00 per share. The total proceeds we received from the offering, net of underwriting discounts and commissions and other offering expenses that we initially paid was $145,935.

Under the terms of the IBP agreement, we are required to pay contingent consideration if the company is able to achieve certain regulatory milestones. The potential undiscounted consideration payable ranges from $0 to $490, depending on whether units being developed are certified for sale by U.S. and foreign regulatory bodies. We currently believe that it is more likely than not that all aspects of the contingency will be achieved and we expect to pay $490 during the year ending March 31, 2021.

As of June 30, 2020, $172,500 in aggregate principal amount Notes was outstanding. The Notes bear interest at a rate of 1.375% payable semi-annually in arrears on February 15 and August 15 of each year, beginning with our first payment made on February 15, 2020. These Notes can be converted prior to maturity if certain conditions are met. We currently expect to settle future conversions of the Notes entirely in shares of our common stock and will reevaluate this policy from time to time in the event that conversion notices are received from holders of the Notes. We were in compliance with all debt agreements at June 30, 2020 and for all prior years presented and have met all debt payment obligations. Refer to Note 7. "Indebtedness" within Item 1. *Financial Statements* for more details on these transactions. We may from time to time repurchase or otherwise retire our debt and take other steps to reduce our debt or otherwise improve our balance sheet. These actions may include retirements or refinancing of outstanding debt, privately negotiated transactions or otherwise. The amount of debt that may be retired, if any, could be material and would be decided at the sole discretion of our Board of Directors and will depend on market conditions, our cash position and other considerations.

We routinely evaluate opportunities for strategic acquisitions. We currently have significant cash and cash equivalents on hand, but future material acquisitions may require that we obtain additional capital, assume additional third-party debt or incur other long-term obligations. We believe that we have the ability to issue more equity or debt in the future in order to finance our acquisition and investment activities.

### Dividends

We have paid regular quarterly dividends since 2003. We declared and paid dividends of $0.16 per share during the three months ended June 30, 2020 as well as each quarter for the year ended March 31, 2020.

In July 2020, we announced that our Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, payable on September 15, 2020, to shareholders of record at the close of business on August 31, 2020.

Page 26

### Cash Flows

Our cash flows from operating, investing, and financing activities were as follows (in thousands):

|  | Three Months Ended June 30, 2020 | 2019 |
| --- | ---: | ---: |
| Net cash provided by operating activities | $2,068 | $724 |
| Net cash (used in) investing activities | (216) | (2,781) |
| Net cash provided by (used in) financing activities | 146,885 | (915) |

Cash flows from operating activities for the three months ended June 30, 2020 provided $2,068, which primarily resulted from increased collections of accounts receivable, partially offset by an increase in the realization of unearned revenues. Cash used in investing was lower during the three months ended June 30, 2020 compared to the three months ended June 30, 2019, which included a cash outlay for the IBP acquisition. Cash provided by financing increased due to proceeds raised through our equity offering, which was completed in June, 2020.

### Contractual Obligations and Other Commercial Commitments

We are party to many contractual obligations that involve commitments to make payments to third parties in the ordinary course of business. For a description of our contractual obligations and other commercial commitments as of March 31, 2020, see our Form 10-K for the fiscal year ended March 31, 2020, filed with the Securities and Exchange Commission on June 1, 2020. During the current three months ended June 30, 2020, there were no material changes with respect to the nature of our contractual obligations and other commercial commitments outside the ordinary course of business. At June 30, 2020, we had contractual obligations for open purchase orders of approximately $4,153 for routine purchases of supplies and inventory, which are payable in less than one year.

### Off-Balance Sheet Arrangements

As of June 30, 2020, we had no off-balance sheet arrangements or obligations.

### Critical Accounting Policies and Estimates

Critical accounting estimates are those that we believe are both significant and require us to make difficult, subjective, or complex judgments, often because we need to estimate the effect of inherently uncertain matters. These estimates are based on historical experience and various other factors that we believe to be appropriate under the circumstance. Actual amounts and results could differ from these estimates made by management. Certain accounting policies that require significant management estimates and are deemed critical to our results of operations or financial position are discussed in our Annual Report on Form 10-K for the year ended March 31, 2020, in the Critical Accounting Policies and Estimates section of “Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.”

## Market risk

As filed, 1,272 characters.

We have no derivative instruments and minimal exposure to commodity market risks. A portion of our operations consist of activities outside of the U.S. and we have currency risk on the transactions in other currencies and translation adjustments resulting from the conversion of our international financial results into the U.S. dollar. We face currency exposures in our global operations as a result of various factors including intercompany currency denominated loans, selling our products in various currencies, purchasing raw materials and equipment in various currencies and tax exposures not denominated in the functional currency. These exposures have increased as a result of the GPT Acquisition, which conducts a substantial portion of its business in Swedish Krona. A hypothetical 10 percent reduction (U.S. dollar strengthening) in currency exchange rates compared to the U.S. dollar would result in an estimated $1,800 reduction in net earnings over a one-year period. Actual changes in market prices or rates may differ from hypothetical changes.

We hold investments in money market funds. As a result, we are exposed to potential loss from market risks that may occur as a result of changes in interest rates, credit quality of the issuer, or other factors.

## Controls and procedures

As filed, 3,640 characters.

### Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are designed to ensure that information required to be disclosed in Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

As of June 30, 2020, we carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report, given the remediation of the material weakness described in more detail below.

### Remediation of Material Weakness

As disclosed in Part II Item 9A. "Controls and Procedures" in our annual report on Form 10-K for the year ended March 31, 2020, during the three months ended March 31, 2020, we identified a material weakness in internal controls related to ineffective information technology general controls ("ITGCs") in the areas of user access and program change management over certain information technology ("IT") systems that support our financial reporting processes.

Beginning during the three months ended March 31, 2020, and continuing through June 30, 2020, we implemented our previously-disclosed remediation plan that included: i) training programs addressing ITGCs and policies around internal controls over financial reporting, which included educating control owners concerning the requirements of each control that they are responsible for; (ii) creation of roles that are responsible for IT compliance and oversight; (iii) development of documentation underlying ITGCs to promote knowledge transfer upon personnel and function changes; (iv) an IT management review and testing plan to monitor ITGCs with a specific focus on systems supporting our financial reporting processes; and (v) enhanced quarterly reporting on the remediation measures to the Audit Committee of the Board of Directors.

During the three months ended June 30, 2020, we completed our testing of the operating effectiveness of the affected ITGC controls and found them to be effective. As a result, we have concluded that the material weakness has been remediated as of June 30, 2020.

### Changes in Internal Control over Financial Reporting

The GPT Acquisition was completed on October 31, 2019. The financial results of GPT are included in our unaudited consolidated financial statements as of June 30, 2020 and for the quarter then ended. The GPT business represented approximately $5,949 of revenues and ($2,176) of net loss, respectively, for the three months ended June 30, 2020. As this acquisition occurred in the third quarter of fiscal year 2020, the scope of our assessment of our internal control over financial reporting does not include GPT. This exclusion is in accordance with the Securities and Exchange Commission’s general guidance that an assessment of a recently acquired business may be omitted from our scope in the year of acquisition.

Page 27

## Risk factors

As filed, 1,099 characters.

We are affected by risks specific to us as well as factors that affect all businesses operating in a global market. The significant factors known to us that could materially adversely affect our business, financial condition, or operating results are described in our Annual Report on Form 10-K for the year ended March 31, 2020, under the heading “Part I – Item 1A. Risk Factors.” The Risk Factors section in our Annual Report on Form 10-K for the year ended March 31, 2020, as updated by this first quarter Form 10-Q including the discussions of the COVID-19 pandemic in this report in Management's Discussion and Analysis, remains current in all material respects. These risk factors do not identify all risks that we face—our operations could also be affected by factors that are not presently known to us or that we currently consider to be immaterial to our operations. Due to risks and uncertainties, known and unknown, our past financial results may not be a reliable indicator of future performance and historical trends should not be used to anticipate results or trends in future periods.

Filed Aug 6, 2020.
Source: SEC EDGAR, the filing index for accession 0001437749-20-016748. Last ingested by Listed: Nov 13, 2026, 07:45 ET. No prices; not investment advice.
